We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Overwhelmingly Supports Boehringer’s Striverdi for COPD
Panel Overwhelmingly Supports Boehringer’s Striverdi for COPD
February 1, 2013
An FDA advisory panel voted 15–1 with one abstention that Boehringer Ingelheim’s (BI) long-acting inhaler Striverdi Respimat has an acceptable risk-benefit profile as a maintenance treatment for chronic obstructive pulmonary disease (COPD).